Skip to content
PodParley
SueWallSt podcast artwork

PODCAST · business

SueWallSt

by SueWallSt

Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how the powerful play the game and sometimes get burned. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Go to ZLK.com for more on the case and follow us for the next corporate faceplant.

Publisher-supplied feed metadata · PodParley refreshed Sep 24, 2026 · Source feed

Subscribe · 0 Bookmark

Episodes

  1. #162 $FSK FS KKR's Credit Quality Crisis: Nonaccrual Loans, Dividend Cut, and Investor Lawsuit

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving FS KKR Capital Corp. ($FSK). We break down allegations that the business development company overstated improvements in portfolio credit quality, restructuring efforts,...

  2. #161 $GLOB Globant's Latin America Growth Story Unravels: Revenue Declines, Layoffs, and Investor Lawsuit

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving Globant ($GLOB). We break down allegations that the technology consulting giant promoted strong growth opportunities across Latin America while facing declining client...

  3. #160 $GPK Graphic Packaging's Inventory Crisis: Guidance Cuts, CEO Exit, and Investor Lawsuit

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit involving Graphic Packaging Holding Company ($GPK). We explore allegations that the company overstated the strength of its business model, inventory management strategy, demand...

  4. #159 $LKQ LKQ's $2.1 Billion Acquisition Problem: FinishMaster Customer Losses and Investor Lawsuit

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit involving LKQ Corporation ($LKQ). We explore allegations that LKQ promoted its Uni-Select and FinishMaster acquisition as a strategic growth driver with strong synergies and...

  5. #158 $PHR Phreesia's Guidance Breakdown: Network Solutions Trouble and a 27% Stock Drop

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving Phreesia ($PHR). We break down allegations that the healthcare technology company overstated visibility into future growth, pharmaceutical marketing demand, and the…

    more

  6. #157 $POET POET's Costly Disclosure: PFIC Tax Trouble, Marvell Fallout, and a 47% Stock Crash

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit involving POET Technologies ($POET). We explore allegations surrounding PFIC tax status disclosures, a controversial executive interview, confidentiality obligations with Marvell...

  7. #156 $RGC Regencell's $14 Billion Mystery: DOJ Investigation, Stock Surge, and Investor Lawsuit

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving Regencell Bioscience Holdings ($RGC). We break down allegations surrounding extreme stock volatility, market manipulation risks, disclosure obligations, a Department of...

  8. #155 $SES SES AI Lawsuit Shock: Battery Deals, AI Claims, and Investor Fallout

    In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit against SES AI Corporation ($SES). Learn about allegations involving battery energy storage deals, AI technology claims, Molecular Universe, revenue growth projections, logistics...

  9. #154 $BW Billion Dollar AI Deal or Billion Dollar Illusion

    Dive into a compelling finance and investing podcast episode exploring Babcock & Wilcox Enterprises $BW and a high profile AI data center deal that captured Wall Street's attention. Perfect for investors, traders, and market enthusiasts, this deep dive examines artificial intelligence...

  10. #153 $UPST AI Model Overdrive When Algorithms Cut Too Deep

    This episode dives into Upstart Holdings $UPST and a high stakes securities case where AI lending promises collided with unexpected model behavior. Built for investors, traders, and fintech watchers, we explore artificial intelligence credit models, loan approvals, macro sensitivity, and revenue...

  11. #152 $UHG From Value Review to Fire Sale The United Homes Collapse

    This episode breaks down United Homes Group $UHG and a dramatic governance clash that turned a “maximize shareholder value” strategy into a steep discounted buyout. Built for investors, traders, and real estate market watchers, we explore board resignations, insider control risk, strategic review...

  12. #151 $STLA EV Ambitions to Billion Euro Reset The Stellantis Shock

    This episode dives into Stellantis $STLA and a massive business reset that stunned investors after bold electrification promises. Built for investors, traders, and auto industry watchers, we break down EV strategy risks, restructuring charges, earnings pressure, and stock volatility. Expect deep...

  13. #150 $NUAI AI Dreams to Oil Field Reality The New Era Collapse

    This episode unpacks New Era Energy and Digital $NUAI and a complex securities case where AI data center ambitions collided with alleged permitting gaps and oil and gas liabilities. Built for investors, traders, and energy tech watchers, we explore regulatory risk, asset retirement obligations,...

  14. #149 $MEDP Book to Bill Breakdown When Cancellations Come Back

    This episode dives into Medpace Holdings $MEDP and a high stakes securities case where strong guidance and “well behaved” cancellations collided with a disappointing book to bill miss. Built for investors, traders, and biotech service watchers, we break down CRO trends, backlog risk…

    more

  15. #148 $BW Billion Dollar Deal or Broken Narrative The Babcock and Wilcox Case

    This episode dives into Babcock and Wilcox $BW and a high stakes AI data center deal that sent the stock soaring before raising serious investor questions. Built for investors, traders, and energy and AI market watchers, we break down backlog growth, contract risk, related party concerns, and…

    more

  16. #147 $VITL ERP Rollout Chaos From Smooth Switch to Supply Shock

    This episode breaks down Vital Farms $VITL and a supply chain disruption story tied to ERP system rollout risks, operational delays, and investor fallout. Built for investors, traders, and consumer goods watchers, we explore inventory systems, shipment slowdowns, retail shelf space loss, and...

  17. #146 $PINS Ad Revenue Reality Check The Pinterest Pullback

    This episode breaks down Pinterest $PINS and a high stakes securities case tied to ad revenue pressure, tariff impacts, and investor expectations. Built for investors, traders, and digital ad watchers, we explore retail advertiser pullbacks, platform monetization risk, restructuring signals, and...

  18. #145 $SMCI AI Boom to Export Control Shock The Super Micro Story

    This episode dives into Super Micro Computer $SMCI and a high stakes controversy where explosive AI server growth collided with alleged export control violations. Built for investors, traders, and tech market watchers, we break down AI infrastructure demand, data center growth, compliance risks,...

  19. #143 $IBRX Breakthrough Hype to FDA Reality Check

    This episode dives into ImmunityBio $IBRX and a biotech controversy where bold cancer cure claims collided with regulatory scrutiny. Built for investors, biotech traders, and market watchers, we break down FDA warning letters, drug approval limits, clinical hype, and stock drops. Expect deep dive...

  20. #142 $GOSS Trial Design Trap The PROSERA Collapse

    This episode unpacks Gossamer Bio $GOSS and a biotech breakdown where trial design risks collided with investor expectations. Built for biotech investors, traders, and market watchers, we explore Phase three trials, placebo response impact, clinical data risk, and stock crashes. Expect deep dive...

  21. #141 $ALDX Clinical Promise to FDA Rejection The Reproxalap Fallout

    This episode dives into Aldeyra Therapeutics $ALDX and a biotech story that flipped from clinical optimism to regulatory shock. Built for investors, biotech traders, and market watchers, we break down drug trials, FDA complete response letters, inconsistent data, and stock collapse risk. Expect...

  22. #140 $PSIX Data Center Dream to Margin Meltdown

    This episode breaks down Power Solutions International $PSIX and a shocking shift from booming data center demand to collapsing margins and investor fallout. Built for traders, investors, and market watchers, we explore earnings volatility, margin compression, production inefficiencies, and stock...

  23. #139 $LU Accounting Shock When Financials Get Restated

    This episode dives into Lufax Holdings $LU and a major accounting controversy involving restated financials, auditor concerns, and internal control failures. Built for investors, traders, and financial analysts, we break down earnings restatements, disclosure risks, audit red flags, and stock…

    more

  24. #138 $HTGC Valuation Illusion Inside the Hercules Capital Controversy

    This episode dives into Hercules Capital $HTGC and a high stakes securities case questioning underwriting discipline, portfolio valuation, and deal sourcing practices. Built for investors, traders, and finance professionals, we break down net asset value N A V, private credit risk, software...

  25. #137 $GEMI Crypto Pivot Chaos From Exchange Growth to Strategy Shock

    This episode unpacks Gemini Space Station $GEMI and a dramatic post IPO shift that stunned investors. Built for crypto traders, retail investors, and market watchers, we break down exchange growth narratives, prediction markets, layoffs, executive exits, and global pullbacks. Expect deep dive...

  26. #136 $COTY Beauty Boom to Bust The Earnings Shock Story

    In this episode, we break down the rise and reality check behind Coty Inc $COTY, uncovering a high stakes securities case tied to beauty industry trends, earnings guidance, and investor expectations. Built for investors, traders, and market watchers, this deep dive explores fragrance sales,...

  27. #135 $CIGL From Sky High Hype to Crash Landing The Concorde Collapse

    This episode breaks down the explosive rise and سقوط of Concorde International Group $CIGL, blending true crime style storytelling with deep dive financial analysis. Built for retail investors, traders, and anyone navigating stock market risk, we unpack alleged WhatsApp scams, social media...

  28. #134 $ATRA From Breakthrough to Breakdown The Atara Biotech Story

    Dive into a gripping finance and biotech podcast episode unpacking Atara Biotherapeutics and the fall from FDA optimism to a securities class action. Perfect for investors, traders, and finance enthusiasts, this episode blends deep dive analysis, storytelling, and market insight. We explore $ATRA...

  29. #133 $IT Strong Guidance or Silent Slowdown Inside Gartner Miss

    Dive into the Gartner $IT controversy as we break down a securities class action tied to contract value growth, consulting revenue weakness, and alleged misleading guidance. This episode is for investors, traders, and anyone following tech services, enterprise demand, and market risk. Expect deep...

  30. #132 $GO Growth Push or Costly Correction Inside Grocery Outlet Drop

    Dive into the Grocery Outlet $GO controversy as we break down a securities class action tied to rapid store expansion, restructuring risks, and alleged misleading growth claims. This episode is for investors, traders, and anyone following retail stocks, expansion strategies, and market…

    more

  31. #131 $ALIT Dividend Confidence or Collapse Inside Alight Unraveling

    Dive into the Alight $ALIT controversy as we break down a securities class action tied to execution failures, weak growth, and alleged misleading statements about margins and dividends. This episode is for investors, traders, and anyone following SaaS, HR tech, and market risk. Expect deep dives,...

  32. #130 $TCOM Antitrust Risk or Missed Warning Inside Trip.com Drop

    Dive into the Trip.com $TCOM controversy as we break down a securities class action tied to antitrust investigations, regulatory risk in China, and alleged misleading disclosures. This episode is for investors, traders, and anyone following tech platforms, global markets, and market volatility....

  33. #129 $SLNO Breakthrough Drug or Hidden Risk Inside Soleno Fallout

    Dive into the Soleno Therapeutics $SLNO controversy as we break down a securities class action tied to drug safety, rare disease treatments, and alleged misleading statements around Vykat XR. This episode is for investors, traders, and anyone following biotech stocks, FDA approvals, and market...

  34. #128 $ODD Beauty Tech or Broken Ads Inside Oddity Tech Shock

    Dive into the Oddity Tech $ODD controversy as we break down a securities class action tied to digital advertising, customer acquisition costs, and algorithm driven disruptions. This episode is for investors, traders, and anyone following ecommerce, tech stocks, and market risk. Expect deep dives,...

  35. #127 $NKTR Trial Trouble When Clinical Confidence Cracks

    Dive into the Nektar Therapeutics $NKTR controversy as we break down a securities class action tied to biotech trials, protocol violations, and alleged misleading statements around clinical execution. This episode is for investors, traders, and anyone following biotech stocks, drug development…

    more

  36. #126 $MNDY Growth Story or Slowing Momentum Inside monday.com Shift

    Dive into the monday.com $MNDY controversy as we break down a securities class action tied to SaaS growth, enterprise sales trends, and shifting long term revenue targets. This episode is for investors, traders, and anyone following tech stocks, cloud platforms, and market volatility. Expect deep...

  37. #125 $EOSE Battery Boom or Broken Ramp Inside Eos Energy Miss

    Dive into the Eos Energy $EOSE controversy as we break down a securities class action tied to battery technology, manufacturing automation, and missed revenue guidance. This episode is for investors, traders, and anyone following energy storage, clean tech, and market risk. Expect deep dives…

    more

  38. #124 $DRVN Restatement Shock When Financials Can’t Be Trusted

    Dive into the Driven Brands $DRVN controversy as we break down a securities class action tied to financial restatements, internal control failures, and accounting errors across multiple years. This episode is for investors, traders, and anyone following earnings quality, corporate governance, and...

  39. #123 $CWH Inventory Control or Margin Collapse Inside Camping World

    Dive into the Camping World $CWH controversy as we break down a securities class action tied to inventory management, margin pressure, and alleged misleading statements about financial discipline. This episode is for investors, traders, and anyone following retail stocks, RV market trends, and...

  40. #122 $CHOW Pump Hype or Engineered Collapse Inside ChowChow Cloud

    Dive into the ChowChow Cloud $CHOW controversy as we break down a securities class action tied to IPO activity, alleged stock manipulation, and social media driven trading schemes. This episode is for investors, traders, and anyone following micro cap stocks, IPO risks, and market volatility....

  41. #121 $BSX Heart Growth Hype or Hidden Slowdown Inside Boston Scientific

    Dive into the Boston Scientific $BSX controversy as we break down a securities class action tied to medical devices, electrophysiology growth, and alleged misleading statements around FARAPULSE adoption. This episode is for investors, traders, and anyone following healthcare stocks, medtech...

  42. #120 $AQST FDA Delay Shock The Allergy Drug Setback Investors Missed

    Dive into the Aquestive Therapeutics $AQST controversy as we break down a securities class action tied to biotech approvals, FDA delays, and alleged misleading timelines around Anaphylm. This episode is for investors, traders, and anyone following biotech stocks, drug approvals, and market...

  43. #119 $APO Wall Street Secrets The Apollo Epstein Controversy

    Dive into the Apollo Global Management $APO controversy as we break down a securities class action tied to alleged undisclosed ties, reputational risk, and investor disclosures. This episode is for investors, traders, and anyone following hedge funds, Wall Street news, and market transparency....

  44. #118 $SNOW Cloud Growth or Hidden Headwinds Inside the Snowflake Drop

    Dive into the Snowflake $SNOW controversy as we break down a securities class action tied to cloud computing, consumption based revenue, and unexpected growth headwinds. This episode is for investors, traders, and anyone following tech stocks, data platforms, and market volatility. Expect deep...

  45. #117 $NAVN IPO Turbulence What Investors Weren’t Told

    Dive into the Navan $NAVN controversy as we break down a securities class action tied to IPO disclosures, rising sales and marketing costs, and post IPO stock declines. This episode is for investors, traders, and anyone following tech stocks, IPOs, and market risk. Expect deep dives, real case...

  46. #116 $LAKE Growth Strategy or Cracks in the Foundation Inside Lakeland Fallout

    Dive into the Lakeland Industries $LAKE controversy as we break down a securities class action tied to acquisitions, operational challenges, and missed financial guidance. This episode is for investors, traders, and anyone following industrial stocks, M and A strategies, and market risk. Expect...

  47. #115 $FBRT Dividend Cut Shock Income Investors Blindsided

    Dive into the Franklin BSP Realty Trust $FBRT controversy as we break down a securities class action tied to REIT dividends, commercial real estate debt, and alleged misleading statements about earnings power. This episode is for income investors, traders, and anyone following dividend stocks,...

  48. #114 $CORT FDA Shock The Approval That Never Came

    Dive into the Corcept Therapeutics $CORT controversy as we break down a securities class action tied to biotech approvals, FDA setbacks, and alleged misleading statements حول relacorilant. This episode is for investors, traders, and anyone following biotech stocks, clinical trials, and market...

  49. #113 $ZYXI Shocking Growth or Alleged Fraud Inside Zynex Collapse

    Dive into the Zynex $ZYXI controversy as we break down a massive securities class action tied to alleged overbilling, medical device supply practices, and inflated revenue growth. This episode is for investors, traders, and anyone following healthcare stocks, fraud allegations, and market risk....

  50. #112 $ENPH Solar Shock Inventory Truth or Revenue Illusion

    Unpack the Enphase Energy $ENPH controversy as we break down a securities class action tied to solar energy, inventory management, and tax credit impacts. This episode is built for investors, traders, and anyone tracking clean energy stocks, earnings volatility, and market risk. We dive into safe...

View all 100 episodes →

Type above to search every episode's transcript for a word or phrase. Matches are scoped to this podcast.

Searching…

We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.

No matches for "" in this podcast's transcripts.

Showing of matches

No topics indexed yet for this podcast.

Loading reviews...

ABOUT THIS SHOW

Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how the powerful play the game and sometimes get burned. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Go to ZLK.com for more on the case and follow us for the next corporate faceplant.

HOSTED BY

SueWallSt

CATEGORIES

business investing

Frequently Asked Questions

How many episodes does SueWallSt have?

SueWallSt currently has 100 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.

What is SueWallSt about?

Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how the powerful play the game and sometimes get burned. We’re not lawyers or accountants, so don’t...

How often does SueWallSt release new episodes?

SueWallSt has 100 episodes. Check the episode list to see recent publication dates and frequency.

Where can I listen to SueWallSt?

You can listen to SueWallSt on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.

Who hosts SueWallSt?

SueWallSt is created and hosted by SueWallSt.
URL copied to clipboard!